HER1/EGFR in Cancer

HER1/EGFR signaling is frequently dysregulated in cancer

• HER1/EGFR signaling may be dysregulated through receptor overexpression, mutation, or both^3-5
• Dysregulated HER1/EGFR signaling has multiple cellular effects, including^1,3
  • Increased cell cycle progression
  • Tumor cell survival and proliferation
  • Increased transcription of genes
  • Cell migration and metastasis

HER1/EGFR in a negative prognostic factor

• In NSCLC, HER1/EGFR has been linked to shorter overall survival¹²
  • Additional clinical research indicates that HER1/EGFR phosphorylation, rather than receptor overexpression, affects prognosis¹⁰
• In pancreatic cancer, HER1/EGFR has been correlated with
  • Higher tumor grade¹³
  • More advanced disease¹⁴
  • Shorter overall survival¹⁴

HER1/EGFR represents a potential therapeutic target

• Methods of targeting could include
  • Targeting HER1/EGFR-specific ligands
  • Targeting the ligand-binding domain of HER1/EGFR
  • Targeting the tyrosine kinase domain of the receptor
  • Targeting downstream signaling pathways

Additional clinical research is needed to better clarify the role of HER1/EGFR in cancer.